Form 4: Akoya Biosciences Director Completes Full Share and Option Disposition Following Quanterix Merger

Akoya Biosciences Director Matthew Winkler has disposed of all his common stock and stock options in Akoya Biosciences, Inc. following its merger with Quanterix Corporation, effective July 8, 2025.

Summary

• Matthew Winkler, a Director of Akoya Biosciences, Inc., has reported the complete disposition of his beneficial ownership in the company.
• The disposition occurred on July 8, 2025, which was the closing date of the merger between Akoya Biosciences, Inc. and Wellfleet Merger Sub, Inc., a wholly owned subsidiary of Quanterix Corporation.
• Akoya Biosciences, Inc. survived the merger as a wholly owned subsidiary of Quanterix Corporation.
• Each outstanding share of Akoya common stock was converted into the right to receive 0.1461 shares of Quanterix common stock and $0.38 in cash.
• Mr. Winkler disposed of 984,513 shares of Akoya common stock.
• He also disposed of all his stock options, totaling 153,731 options across various strike prices ($21.95, $11.24, $5.7, $2.01).
• Options with an exercise price equal to or greater than the Per Share Merger Consideration were automatically terminated and cancelled for no consideration.

Sentiment

Score: 7

Explanation: The document reports the successful completion of a pre-announced merger, which provides a clear exit for Akoya shareholders and integrates the company into a larger entity. While some option holders may have lost value, the overall event is a planned strategic transaction.

Positives

• The merger provides Akoya Biosciences shareholders with a combination of Quanterix stock and cash, offering liquidity and continued exposure to the combined entity.
• The completion of the merger signifies a strategic consolidation in the life sciences tools sector.

Negatives

• Akoya Biosciences common stock and options are no longer outstanding, meaning former shareholders and option holders no longer have direct ownership in Akoya.
• Options with exercise prices equal to or greater than the merger consideration were cancelled for no consideration, potentially resulting in a loss for those option holders.

Risks

• The value of the stock consideration (Quanterix common stock) is subject to market fluctuations, introducing post-merger risk for former Akoya shareholders.
• Option holders whose exercise price was at or above the merger consideration received no value for their options.

Future Outlook

The document indicates the completion of a merger, leading to Akoya Biosciences becoming a wholly owned subsidiary of Quanterix. This implies a future where Akoya's operations are integrated under Quanterix.

Industry Context

This merger represents a consolidation within the life sciences tools and diagnostics industry, potentially aiming to leverage synergies between Akoya's spatial biology solutions and Quanterix's ultra-sensitive immunoassay platforms. Such mergers are common as companies seek to expand their market reach, technology portfolios, and competitive advantages.

Comparison to Industry Standards

• The merger consideration structure, involving both stock and cash, is a common approach in corporate acquisitions, offering a balance of immediate liquidity and participation in the acquiring company's future growth.
• The cancellation of out-of-the-money options for no consideration is standard practice in mergers where the acquisition price does not exceed the option's strike price.
• The per-share stock consideration of 0.1461 shares of Quanterix and $0.38 cash per Akoya share reflects the negotiated valuation, which would typically be benchmarked against recent transactions in the diagnostics and life sciences tools sector, considering factors like revenue multiples, EBITDA multiples, and strategic fit. Specific comparable companies or projects are not detailed in this Form 4.

Stakeholder Impact

• Shareholders (Akoya): Received cash and Quanterix stock, converting their ownership in Akoya into a stake in the combined entity and immediate liquidity.
• Option Holders (Akoya): Those with in-the-money options likely received value, while those with out-of-the-money options had them cancelled for no consideration.
• Employees (Akoya): Akoya becomes a subsidiary of Quanterix, potentially leading to integration efforts, changes in reporting structures, and potential synergies or redundancies.
• Customers (Akoya/Quanterix): May benefit from a broader product portfolio and integrated solutions from the combined company.

Next Steps

• Integration of Akoya Biosciences into Quanterix Corporation.
• Former Akoya shareholders will receive Quanterix common stock and cash as per the merger terms.

Key Dates

Recommendation

Keywords

Akoya Biosciences, Quanterix Corporation, Merger, SEC Form 4, Insider Trading, Stock Disposition, Option Disposition, Corporate Acquisition, Life Sciences, Biotechnology